Intratio
Loading...
Skip to main content
Model output · Signal date Oct. 16, 2026

Daily Signals

2758 companies scored · Alpha · vs marketSwitch to Total · 30D 90D

Signal date 2026-10-16 Cut-offs from the 2026-10-16 run
Companies scored 2758 IC ≥ 0 · market cap ≥ $100M
Median forecast -0.41% Alpha · 90D
Long–short spread +5.19% Strong Buy minus Strong Sell, mean
Median IC 0.27 Spearman · 90D
Rating changes ▲ 278 ▼ 463 vs the previous run
Cross-section

Distribution of the day's forecasts

90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Signals · All

296 companies

Sorted by market cap ↓ · forecast rankings are part of the paid plans

# Ticker Sector IC Mkt cap Rating 30D 90D Δ
101 PRGOPERRIGO Co plc Life Sciences 0.67 $2.3B Unlock rating and forecasts
102 PGENPRECIGEN, INC. Life Sciences 0.32 $2.3B Unlock rating and forecasts
103 HRMYHarmony Biosciences Holdings, Inc. Life Sciences 0.49 $2.2B Unlock rating and forecasts
104 SUPNSUPERNUS PHARMACEUTICALS, INC. Life Sciences 0.10 $2.2B Unlock rating and forecasts
105 AUPHAurinia Pharmaceuticals Inc. Life Sciences 0.11 $2.2B Neutral -0.35% -0.73% ·
106 CLDXCelldex Therapeutics, Inc. Life Sciences 0.15 $2.2B Unlock rating and forecasts
107 VRDNViridian Therapeutics, Inc.\DE Life Sciences 0.46 $2.2B Neutral -0.28% -0.54% ▼ 1
108 VCELVericel Corp Life Sciences 0.40 $2.1B Neutral -0.32% -0.64% ▼ 1
109 SLSSELLAS Life Sciences Group, Inc. Life Sciences 0.41 $2.0B Unlock rating and forecasts
110 BCRXBIOCRYST PHARMACEUTICALS INC Life Sciences 0.23 $2.0B Unlock rating and forecasts
111 LKFTLakefront Biotherapeutics NV Life Sciences 0.38 $2.0B Neutral -0.22% -0.40% ·
112 TRLVTrulieve Cannabis Corp. Life Sciences 0.56 $1.9B Unlock rating and forecasts
113 XERSXeris Biopharma Holdings, Inc. Life Sciences 0.00 $1.9B Unlock rating and forecasts
114 IMNMImmunome Inc. Life Sciences 0.22 $1.9B Unlock rating and forecasts
115 AGIOAGIOS PHARMACEUTICALS, INC. Life Sciences 0.14 $1.9B Unlock rating and forecasts
116 NVAXNOVAVAX INC Life Sciences 0.13 $1.9B Unlock rating and forecasts
117 MLYSMineralys Therapeutics, Inc. Life Sciences 0.24 $1.8B Unlock rating and forecasts
118 ALVOAlvotech Life Sciences 0.17 $1.8B Unlock rating and forecasts
119 MRVIMARAVAI LIFESCIENCES HOLDINGS, INC. Life Sciences 0.68 $1.8B Unlock rating and forecasts
120 PVLAPALVELLA THERAPEUTICS, INC. Life Sciences 0.13 $1.7B Unlock rating and forecasts
121 XNCRXencor Inc Life Sciences 0.29 $1.7B Unlock rating and forecasts
122 TRVITrevi Therapeutics, Inc. Life Sciences 0.30 $1.7B Unlock rating and forecasts
123 URGNUroGen Pharma Ltd. Life Sciences 0.55 $1.7B Unlock rating and forecasts
124 VIRVir Biotechnology, Inc. Life Sciences 0.36 $1.7B Unlock rating and forecasts
125 SDGRSchrodinger, Inc. Life Sciences 0.35 $1.7B Unlock rating and forecasts
126 ANIPANI PHARMACEUTICALS INC Life Sciences 0.58 $1.7B Unlock rating and forecasts
127 NTLAIntellia Therapeutics, Inc. Life Sciences 0.43 $1.6B Unlock rating and forecasts
128 PAHCPHIBRO ANIMAL HEALTH CORP Life Sciences 0.32 $1.6B Unlock rating and forecasts
129 NUVBNuvation Bio Inc. Life Sciences 0.10 $1.6B Unlock rating and forecasts
130 STOKStoke Therapeutics, Inc. Life Sciences 0.20 $1.6B Unlock rating and forecasts
131 GENBGenerate Biomedicines, Inc. Life Sciences 0.20 $1.6B Unlock rating and forecasts
132 QUREuniQure N.V. Life Sciences 0.12 $1.5B Unlock rating and forecasts
133 OCULOCULAR THERAPEUTIX, INC Life Sciences 0.08 $1.5B Unlock rating and forecasts
134 INVAInnoviva, Inc. Life Sciences 0.07 $1.5B Neutral -0.24% -0.45% ·
135 KRSAKorsana Biosciences, Inc. Life Sciences 0.15 $1.5B Neutral -0.18% -0.33% ·
136 CMPSCOMPASS Pathways plc Life Sciences 0.34 $1.5B Unlock rating and forecasts
137 PCRXPacira BioSciences, Inc. Life Sciences 0.27 $1.4B Neutral -0.14% -0.24% ·
138 ETONEton Pharmaceuticals, Inc. Life Sciences 0.10 $1.4B Unlock rating and forecasts
139 RAREUltragenyx Pharmaceutical Inc. Life Sciences 0.14 $1.4B Unlock rating and forecasts
140 COAGHemab Therapeutics Holdings, Inc. Life Sciences 0.46 $1.4B Neutral -0.33% -0.67% ·
141 ANABANAPTYSBIO, INC Life Sciences 0.27 $1.4B Unlock rating and forecasts
142 RAPPRapport Therapeutics, Inc. Life Sciences 0.05 $1.3B Unlock rating and forecasts
143 TYRATyra Biosciences, Inc. Life Sciences 0.12 $1.3B Unlock rating and forecasts
144 LBRXLB PHARMACEUTICALS INC Life Sciences 0.21 $1.2B Unlock rating and forecasts
145 TSHATaysha Gene Therapies, Inc. Life Sciences 0.03 $1.2B Unlock rating and forecasts
146 OMEROMEROS CORP Life Sciences 0.15 $1.2B Unlock rating and forecasts
147 OPKOPKO HEALTH, INC. Life Sciences 0.39 $1.1B Unlock rating and forecasts
148 GHRSGH Research PLC Life Sciences 0.25 $1.1B Unlock rating and forecasts
149 BCAXBicara Therapeutics Inc. Life Sciences 0.17 $1.1B Unlock rating and forecasts
150 AMPHAmphastar Pharmaceuticals, Inc. Life Sciences 0.40 $1.1B Neutral -0.30% -0.60% ·
101–150 of 296 Previous Next
Since the previous run

Rating changes

▲ 278▼ 463
Which companies were upgraded or downgraded is part of the paid plans.
Next step

Unlock the full ranking

Every company's rating, its 30- and 90-day forecasts, the forecast and IC-weighted rankings, the daily rating changes and CSV export.

See plans Create a free account
Methodology

Ratings are relative: the forecasts of the latest complete daily run (2026-10-16) are ranked and cut at the 15th, 35th, 65th and 85th percentiles, so Strong Sell is the bottom 15%, Sell the next 20%, Neutral the middle 30%, Buy the next 20% and Strong Buy the top 15%. Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. IC is the company's Spearman information coefficient between its past forecasts and the realised returns at the selected horizon; IC-weighted ranking multiplies each forecast by its IC (negative IC counts as zero). Δ is the rating move since the company's previous signal, in rating steps. Each company shows its latest signal, including one from a run still in progress; every signal is rated against the cut-offs above. Quantitative research output, not investment advice.